Loss of SETD2 expression in NPC affects 20 classic signaling pathways closely related to tumors, suggesting the potential feasibility of SETD2-targeted therapy (Zeng et al., 2019). This evidence concerns the gene SETD2 and nasopharyngeal carcinoma.